中国现代医生
中國現代醫生
중국현대의생
CHINA MODERN DOCTOR
2014年
26期
61-63
,共3页
阿立哌唑%剂量%认知功能%D2受体占有率%5HT1A/D2受体部分激动剂的平衡状态
阿立哌唑%劑量%認知功能%D2受體佔有率%5HT1A/D2受體部分激動劑的平衡狀態
아립고서%제량%인지공능%D2수체점유솔%5HT1A/D2수체부분격동제적평형상태
Aripiprazole%Dosage%Cognitive function%D2 receptor occupancy%Balancing status between 5HT1A/D2 partial agonists
目的：探求阿立哌唑的剂量对服用利培酮的稳定期门诊精神分裂症患者认知功能的影响。方法将43例服用利培酮的稳定期门诊精神分裂症患者随机分为两组，对照组(n=22)添加(20~30)mg/d阿立哌唑，研究组(n=21)添加(5~15)mg/d阿立哌唑，治疗时间12周。分别用精神分裂症认知功能简明成套测评量表(BACS)中文版和阳性和阴性症状量表(PANSS)评估疗效，用副反应量表(TESS)评价治疗期间发生的不良反应。结果两组不良反应发生率比较，差异无统计学意义(P>0.05)，利培酮添加(5~15)mg/d阿立哌唑对患者的部分认知功能和阴性症状有明显改善，而添加(20~30)mg/d阿立哌唑，尽管和前者一样能改善运动速度(MS)和阴性症状，但对工作记忆(WM)和执行功能(EF)有显著损害(P<0.01)。结论利培酮添加低剂量而非高剂量的阿立哌唑对认知功能改善最佳。这一结果仍需大量和长期的研究加以确定。
目的：探求阿立哌唑的劑量對服用利培酮的穩定期門診精神分裂癥患者認知功能的影響。方法將43例服用利培酮的穩定期門診精神分裂癥患者隨機分為兩組，對照組(n=22)添加(20~30)mg/d阿立哌唑，研究組(n=21)添加(5~15)mg/d阿立哌唑，治療時間12週。分彆用精神分裂癥認知功能簡明成套測評量錶(BACS)中文版和暘性和陰性癥狀量錶(PANSS)評估療效，用副反應量錶(TESS)評價治療期間髮生的不良反應。結果兩組不良反應髮生率比較，差異無統計學意義(P>0.05)，利培酮添加(5~15)mg/d阿立哌唑對患者的部分認知功能和陰性癥狀有明顯改善，而添加(20~30)mg/d阿立哌唑，儘管和前者一樣能改善運動速度(MS)和陰性癥狀，但對工作記憶(WM)和執行功能(EF)有顯著損害(P<0.01)。結論利培酮添加低劑量而非高劑量的阿立哌唑對認知功能改善最佳。這一結果仍需大量和長期的研究加以確定。
목적：탐구아립고서적제량대복용리배동적은정기문진정신분렬증환자인지공능적영향。방법장43례복용리배동적은정기문진정신분렬증환자수궤분위량조，대조조(n=22)첨가(20~30)mg/d아립고서，연구조(n=21)첨가(5~15)mg/d아립고서，치료시간12주。분별용정신분렬증인지공능간명성투측평량표(BACS)중문판화양성화음성증상량표(PANSS)평고료효，용부반응량표(TESS)평개치료기간발생적불량반응。결과량조불량반응발생솔비교，차이무통계학의의(P>0.05)，리배동첨가(5~15)mg/d아립고서대환자적부분인지공능화음성증상유명현개선，이첨가(20~30)mg/d아립고서，진관화전자일양능개선운동속도(MS)화음성증상，단대공작기억(WM)화집행공능(EF)유현저손해(P<0.01)。결론리배동첨가저제량이비고제량적아립고서대인지공능개선최가。저일결과잉수대량화장기적연구가이학정。
Objective To probe the effects of dosages of aripiprazole on cognitive function of stabilized schizophrenic outpatients treated with risperidone. Methods A totol of 43 stabilized schizophrenic outpatients received risperidone were randomly divided into two groups. Aripiprazole added to control group (n=22)was taken by (20~30)mg/d and the study group(n=21)did by (5~15) mg/d,respectively, for 12 weeks. Brief Assessment of Cognition in Schizophrenia (BACS,Chinese edition)and Positive and Negative Syndrome Scale (PANSS)were used to evaluate efficacy. Treatment Emergent Symptom Scale (TESS) was used to evaluate adverse effects during this trial. Results The occurring rates of adverse effects for the two groups were not significantly different (P>0.05). Risperidone augmentation with aripiprazole by(5~15)mg/d significantly improved partial cognitive function and negative symptoms for these patients. Add-on treat-ment with aripiprazole by (20~30) mg/d significantly impair working memory(WM) and executive function (EF) (P<0.01), although that significantly improved motor speed (MS) and negative symptoms as the former did. Conclusion Risperidone augmentation with a lower rather than higher dosage of aripiprazole would improve cognitive function most favorably. These findings need further substantial and long-term trials to be established .
